Wella Company Names Annie Young-Scrivner as CEO
Today, KKR named Annie Young-Scrivner as the new Chief Executive Officer (CEO) of the Wella Company (“Wella” or the “Company”), one of the world’s leading beauty companies with iconic brands including Wella Professionals, Clairol, OPI, Nioxin, and ghd. The appointment will become effective upon close of the previously announced transaction in which KKR is acquiring 60% of Wella from Coty Inc. (NYSE:COTY) (“Coty”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005353/en/
(Photo: Business Wire)
Ms. Young-Scrivner joins Wella from GODIVA Chocolatier (“GODIVA”) where she served as CEO for the last three years. Her tenure at GODIVA is marked by accelerating growth with expansion into new channels and categories to make the iconic brand more accessible to consumers, while honoring the brand’s heritage. In addition to being the driving force behind GODIVA’s social impact efforts to empower women, Ms. Young-Scrivner also led the enhancement of GODIVA’s digital experience, making it a critical component to the brand’s ecosystem.
During her three-decade career, Ms. Young-Scrivner has demonstrated exceptional strength in brand, digital, and talent development across different channels. Having worked in more than 30 countries around the world, she brings a deep understanding of global markets. Prior to GODIVA, Ms. Young-Scrivner spent seven years in a number of senior positions at Starbucks Corporation (“Starbucks”) where she helped elevate the brand and customer experience while fueling an innovation pipeline that led to double-digit growth. Her leadership on digital and loyalty helped Starbucks’ operations across the globe to engage with its consumer in more meaningful ways. She started her career at PepsiCo Inc. where she held senior leadership roles in sales, marketing and general management during her 19-year tenure with the business.
“We are thrilled that Annie will bring her tremendous passion for the consumer sector, her commitment to diverse and inclusive organizations, and her proven track record of building the value of consumer brands and businesses to the newly formed Wella Company,” said Tim Franks, Partner at KKR and Head of Consumer & Retail in its European Private Equity business.
“Given Annie’s vast global experience in working with B2B and B2C businesses and her intuitive understanding of digital engagement in consumer-centric industries, we are confident she will help unlock the true potential of Wella’s portfolio,” said Nancy Ford, Managing Director at KKR in the Americas Private Equity business.
“I am honored to join Wella at such a pivotal time in the brand’s history as it celebrates 140 years of partnering with beauty professionals and salon owners,” Ms. Young-Scrivner said. “I’ve long admired Wella’s iconic brands and breakthrough innovations, and I am looking forward to engaging with the team as we work to grow the portfolio of brands and increase the Company’s share of the $90 billion Hair and Nail beauty category.”
Current President of Coty’s Professional and Retail Hair businesses, Sylvie Moreau, will remain in her role until the transaction between KKR and Coty closes. “I would like to thank Sylvie for leaving behind a wonderful legacy, a remarkable team and a solid foundation from which we will grow,” said Ms. Young-Scrivner.
After the transaction closes, the Wella Company will operate as a separate company with its own management team and operational structures. Wella will be comprised of the assets of Coty’s Professional and Retail Hair businesses, including the Wella Professional, Clairol, OPI, Nioxin and ghd brands, which are valued at $4.3 billion on a cash- and debt-free basis under the terms of the transaction. KKR will own 60% of the Company and Coty will own the remaining 40%.
As CEO, Ms. Young-Scrivner will report to Wella’s Board of Directors. The standalone Wella Company is expected to have an estimated 6,000 employees and remain a top global player in the professional beauty industry, serving over 250,000 hair and nail salons in over 100 countries and serving consumers globally through its iconic retail brands.
The transaction is expected to close by the end of the year.
Annie Young-Scrivner Biography
Ms. Young-Scrivner served as CEO of GODIVA Chocolatier since August 2017. Prior to joining GODIVA, she served in a variety of senior executive roles at Starbucks Corporation since 2009, including: Executive Vice President, Global Digital & Loyalty Development; President, Teavana & Executive Vice President of Global Tea; President of Starbucks Canada; and Global Chief Marketing Officer & President of Tazo Tea. Prior to her time at Starbucks, Ms. Young-Scrivner spent 19 years at PepsiCo, serving in senior leadership positions in sales, marketing and general management including: Chief Marketing Officer and Head of Sales for Quaker Foods and Snacks Division; Chairman and Region President of PepsiCo Foods Greater China; and Vice President and General Manager of PepsiCo’s Target team.
Ms. Young-Scrivner currently serves on the Board of Directors of Tiffany & Co., and YUM! Brands and previously served on the Board of Macy’s Inc. Ms. Young-Scrivner holds a B.A. from the Foster School of Business, University of Washington, and an Executive M.B.A. from the Carlson School of Business, University of Minnesota. She continued her executive education at IMD, Switzerland, Yale School of Management, Darden School of Management at University of Virginia.
About the Wella Company
The Wella Company* is one of the world’s leading beauty companies, comprised of a family of icons such as Wella Professionals, Clairol, OPI, Nioxin and ghd. With 6,000 employees globally, presence in over 100 countries, the Wella Company and its brands are on a mission to enable consumers to look and feel their true self through the power of positive change. The Wella Company is co-created and designed for the beauty junkies of today and tomorrow and remains committed to diversity & inclusion, sustainability, and a range of social causes. Further information about the Wella Company can be found here: www.wellacompany.com.
*The new company will only be operational under the Wella Company name and logo upon the deal’s closing.
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, credit and real assets, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.
Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, hair color and styling, and skin and body care. Coty is the global leader in fragrance, a strong number two in professional hair color & styling, and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com.
+41 79 543 1952
+44 7557 549 325
Kristi Huller / Cara Major / Miles Radcliffe-Trenner
+49 172 751 2680
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Process Sensing Technologies, a Battery Ventures Company, Announces New Majority Investment from AEA Investors1.12.2020 06:01:00 CET | Press release
Process Sensing Technologies (“PST”), a global manufacturer of instruments, analyzers and sensors for precision measurement and monitoring in a variety of critical industries, announced that global private-equity firm AEA Investors LP (“AEA”) has made a majority investment in the company. PST backer Battery Ventures will maintain a minority stake in the business. Baird acted as exclusive sell-side advisor; other terms of the transaction were not disclosed. PST—a platform constructed under Battery’s ownership comprising seven global businesses—sells its sensors and other technologies into industries including pharmaceuticals, life sciences, specialty gases, petrochemicals, food-and-beverage, semiconductors and building automation. The company’s products measure moisture, oxygen and pressure, among other things, and help improve customers’ profitability while helping them stay compliant with often-stringent industry regulations. Battery began the PST platform journey with its acquisition
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited1.12.2020 00:00:00 CET | Press release
Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (“Takeda”) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would acquire 18 "Primary Care" product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, "Celltrion Asia Pacific Pte, Ltd."1 ("Celltrion APAC"). Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Eda
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific1.12.2020 00:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda’s Growth & Emerging Markets Business Unit. This divestment agreement was first announced in June 2020. The divested portfolio includes pharmaceutical products and OTC products in the Cardiovascular, Diabetes and General Medicine therapeutic areas, sold in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. The products, while addressing key patient needs in these countries and territories, are outside of the business areas Takeda has chosen as core to its global long-term growth. As part of the deal, Takeda will continue to manufacture the portfol
Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE ® ) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)30.11.2020 22:58:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need. ONIVYDE® is currently approved in the United States and in Europe in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE® is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. An ongoing Phase III randomized study (RESILIENT; NCT03088813) trial is being conducted to assess the efficacy and safety of investigational irinotecan liposome injection (ONIVYDE®) as a monotherapy for SCLC study patients who have progressed on or a
Amblin Partners Announces New Multi-Year Film Distribution Partnership With Universal Filmed Entertainment Group30.11.2020 22:00:00 CET | Press release
Amblin Partners today announced a new multi-year film distribution partnership with Universal Filmed Entertainment Group, as well as a series of new agreements that chart a clear course for the next phase of growth for one of the world’s leading independent film and television studios. The new deals were announced this morning by Steven Spielberg, Amblin’s Founder and Chairman. Remarked Spielberg: “My decades-long relationship with Universal truly transcends any single business deal, and to once again renew our corporate vows reaffirms that Universal is Amblin’s home. In addition to Universal, we are blessed to continue forward with a global family of partners, including Alibaba, eOne and Reliance, each of which has supported us for many years and enabled our storytelling to touch the lives of millions of moviegoers around the world. I would also like to extend my deepest gratitude to my dear friends Jeff Skoll and David Linde for an incredible run as formal partners; and my congratula
Little Cinema Taps Verimatrix To Secure Hollywood’s Virtual Premiere Events30.11.2020 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that New York-based Little Cinema deployed Verimatrix Watermarking and Multi-DRM technologies for its virtual premieres and previews. A groundbreaking digital studio, Little Cinema has partnered with Netflix, ABC, CBS, HBO Max, and Warner Media to produce state-of-the-art virtual premiere events for an industry that used to rely solely on in-person debuts. To fulfill the enhanced protection requirements for this high-value early-release content, Little Cinema looked to Verimatrix and its Secure Cloud. These innovative and highly-interactive virtual streaming events have made waves in Hollywood, earning the studio recognition in BBC News, Vogue, Variety, Vanity Fair, The Hollywood Reporter, and more. “Verimatrix supplies us with the needed anti-piracy protections and overall peace of mind that Hollywood studios demand when switching to virtual events